TCT-819 Prediabetes and its Impact on 1-Year Clinical Outcome After Treatment with Newer-Generation Drug-eluting Stents in 2,986 All-Comer Patients

Marlies Kok, Clemens von Birgelen, Paolo Zocca, Marije Lowik, Peter Danse, Carl Schotborgh, Martijn Scholte, Marc Hartmann, Cees Doelman, Gert Kant, R. Melvyn Tjon Joe Gin, Martin Stoel, K. Gert van Houwelingen, Gerard C.M. Linssen, Carine J.M. Doggen, Liefke van der Heijden

Research output: Contribution to journalArticleAcademic

Abstract

BACKGROUND Prediabetes (Pre-DM) is a risk factor state for developing diabetes mellitus (DM). Yet it is unclear whether detection of Pre-DM by routine assessment of glycated haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) among patients undergoing percutaneous coronary intervention (PCI) may help identify subjects with increased event risk. We assessed in all-comers who underwent PCI with contemporary drug-eluting stents (DES) the relation between glycaemia status and 1-year clinical outcome. METHODS HbA1c and FPG was determined in 2,362 non-DM participants in the multicenter, randomized, investigator-initiated TWENTE III trial, in order to identify Pre-DM (HbA1c 42-47mmol/mol; FPG 6.1- 6.9 mmol/L) and DM (HbA1c>=48mmol/mol; FPG >7 mmol/L). Another 624 patients had medically treated DM. The main clinical outcome parameter was a composite endpoint consisting of death, myocardial infarction, or revascularisation. RESULTS Glycaemic state was known in 2,986 trial participants: Pre- DM was present in 324 (11%), DM in 793 (27%), and normoglycaemia in 1,869 (63%) patients. Patients with Pre-DM and DM differed from normoglycemic patients in cardiovascular risk factors. The composite clinical endpoint in Pre-DM occurred in 11.1%, in DM in 10.5%, and in normoglycemic patients in 5.7% (p
Original languageEnglish
Pages (from-to)B333
JournalJournal of the American College of Cardiology
Volume70
Issue number18
DOIs
Publication statusPublished - Oct 2017

Fingerprint

Prediabetic State
Drug-Eluting Stents
Diabetes Mellitus
Fasting
Glucose
Hemoglobins
Percutaneous Coronary Intervention
Myocardial Revascularization
Glycosylated Hemoglobin A

Cite this

Kok, Marlies ; von Birgelen, Clemens ; Zocca, Paolo ; Lowik, Marije ; Danse, Peter ; Schotborgh, Carl ; Scholte, Martijn ; Hartmann, Marc ; Doelman, Cees ; Kant, Gert ; Tjon Joe Gin, R. Melvyn ; Stoel, Martin ; Gert van Houwelingen, K. ; Linssen, Gerard C.M. ; Doggen, Carine J.M. ; van der Heijden, Liefke. / TCT-819 Prediabetes and its Impact on 1-Year Clinical Outcome After Treatment with Newer-Generation Drug-eluting Stents in 2,986 All-Comer Patients. In: Journal of the American College of Cardiology. 2017 ; Vol. 70, No. 18. pp. B333.
@article{c2919de56aae487abcea62d076e71e51,
title = "TCT-819 Prediabetes and its Impact on 1-Year Clinical Outcome After Treatment with Newer-Generation Drug-eluting Stents in 2,986 All-Comer Patients",
abstract = "BACKGROUND Prediabetes (Pre-DM) is a risk factor state for developing diabetes mellitus (DM). Yet it is unclear whether detection of Pre-DM by routine assessment of glycated haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) among patients undergoing percutaneous coronary intervention (PCI) may help identify subjects with increased event risk. We assessed in all-comers who underwent PCI with contemporary drug-eluting stents (DES) the relation between glycaemia status and 1-year clinical outcome. METHODS HbA1c and FPG was determined in 2,362 non-DM participants in the multicenter, randomized, investigator-initiated TWENTE III trial, in order to identify Pre-DM (HbA1c 42-47mmol/mol; FPG 6.1- 6.9 mmol/L) and DM (HbA1c>=48mmol/mol; FPG >7 mmol/L). Another 624 patients had medically treated DM. The main clinical outcome parameter was a composite endpoint consisting of death, myocardial infarction, or revascularisation. RESULTS Glycaemic state was known in 2,986 trial participants: Pre- DM was present in 324 (11{\%}), DM in 793 (27{\%}), and normoglycaemia in 1,869 (63{\%}) patients. Patients with Pre-DM and DM differed from normoglycemic patients in cardiovascular risk factors. The composite clinical endpoint in Pre-DM occurred in 11.1{\%}, in DM in 10.5{\%}, and in normoglycemic patients in 5.7{\%} (p",
author = "Marlies Kok and {von Birgelen}, Clemens and Paolo Zocca and Marije Lowik and Peter Danse and Carl Schotborgh and Martijn Scholte and Marc Hartmann and Cees Doelman and Gert Kant and {Tjon Joe Gin}, {R. Melvyn} and Martin Stoel and {Gert van Houwelingen}, K. and Linssen, {Gerard C.M.} and Doggen, {Carine J.M.} and {van der Heijden}, Liefke",
year = "2017",
month = "10",
doi = "10.1016/j.jacc.2017.09.1029",
language = "English",
volume = "70",
pages = "B333",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier",
number = "18",

}

Kok, M, von Birgelen, C, Zocca, P, Lowik, M, Danse, P, Schotborgh, C, Scholte, M, Hartmann, M, Doelman, C, Kant, G, Tjon Joe Gin, RM, Stoel, M, Gert van Houwelingen, K, Linssen, GCM, Doggen, CJM & van der Heijden, L 2017, 'TCT-819 Prediabetes and its Impact on 1-Year Clinical Outcome After Treatment with Newer-Generation Drug-eluting Stents in 2,986 All-Comer Patients', Journal of the American College of Cardiology, vol. 70, no. 18, pp. B333. https://doi.org/10.1016/j.jacc.2017.09.1029

TCT-819 Prediabetes and its Impact on 1-Year Clinical Outcome After Treatment with Newer-Generation Drug-eluting Stents in 2,986 All-Comer Patients. / Kok, Marlies; von Birgelen, Clemens; Zocca, Paolo; Lowik, Marije; Danse, Peter; Schotborgh, Carl; Scholte, Martijn; Hartmann, Marc; Doelman, Cees; Kant, Gert; Tjon Joe Gin, R. Melvyn; Stoel, Martin; Gert van Houwelingen, K.; Linssen, Gerard C.M.; Doggen, Carine J.M.; van der Heijden, Liefke.

In: Journal of the American College of Cardiology, Vol. 70, No. 18, 10.2017, p. B333.

Research output: Contribution to journalArticleAcademic

TY - JOUR

T1 - TCT-819 Prediabetes and its Impact on 1-Year Clinical Outcome After Treatment with Newer-Generation Drug-eluting Stents in 2,986 All-Comer Patients

AU - Kok, Marlies

AU - von Birgelen, Clemens

AU - Zocca, Paolo

AU - Lowik, Marije

AU - Danse, Peter

AU - Schotborgh, Carl

AU - Scholte, Martijn

AU - Hartmann, Marc

AU - Doelman, Cees

AU - Kant, Gert

AU - Tjon Joe Gin, R. Melvyn

AU - Stoel, Martin

AU - Gert van Houwelingen, K.

AU - Linssen, Gerard C.M.

AU - Doggen, Carine J.M.

AU - van der Heijden, Liefke

PY - 2017/10

Y1 - 2017/10

N2 - BACKGROUND Prediabetes (Pre-DM) is a risk factor state for developing diabetes mellitus (DM). Yet it is unclear whether detection of Pre-DM by routine assessment of glycated haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) among patients undergoing percutaneous coronary intervention (PCI) may help identify subjects with increased event risk. We assessed in all-comers who underwent PCI with contemporary drug-eluting stents (DES) the relation between glycaemia status and 1-year clinical outcome. METHODS HbA1c and FPG was determined in 2,362 non-DM participants in the multicenter, randomized, investigator-initiated TWENTE III trial, in order to identify Pre-DM (HbA1c 42-47mmol/mol; FPG 6.1- 6.9 mmol/L) and DM (HbA1c>=48mmol/mol; FPG >7 mmol/L). Another 624 patients had medically treated DM. The main clinical outcome parameter was a composite endpoint consisting of death, myocardial infarction, or revascularisation. RESULTS Glycaemic state was known in 2,986 trial participants: Pre- DM was present in 324 (11%), DM in 793 (27%), and normoglycaemia in 1,869 (63%) patients. Patients with Pre-DM and DM differed from normoglycemic patients in cardiovascular risk factors. The composite clinical endpoint in Pre-DM occurred in 11.1%, in DM in 10.5%, and in normoglycemic patients in 5.7% (p

AB - BACKGROUND Prediabetes (Pre-DM) is a risk factor state for developing diabetes mellitus (DM). Yet it is unclear whether detection of Pre-DM by routine assessment of glycated haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) among patients undergoing percutaneous coronary intervention (PCI) may help identify subjects with increased event risk. We assessed in all-comers who underwent PCI with contemporary drug-eluting stents (DES) the relation between glycaemia status and 1-year clinical outcome. METHODS HbA1c and FPG was determined in 2,362 non-DM participants in the multicenter, randomized, investigator-initiated TWENTE III trial, in order to identify Pre-DM (HbA1c 42-47mmol/mol; FPG 6.1- 6.9 mmol/L) and DM (HbA1c>=48mmol/mol; FPG >7 mmol/L). Another 624 patients had medically treated DM. The main clinical outcome parameter was a composite endpoint consisting of death, myocardial infarction, or revascularisation. RESULTS Glycaemic state was known in 2,986 trial participants: Pre- DM was present in 324 (11%), DM in 793 (27%), and normoglycaemia in 1,869 (63%) patients. Patients with Pre-DM and DM differed from normoglycemic patients in cardiovascular risk factors. The composite clinical endpoint in Pre-DM occurred in 11.1%, in DM in 10.5%, and in normoglycemic patients in 5.7% (p

UR - http://www.mendeley.com/research/tct819-prediabetes-impact-1year-clinical-outcome-after-treatment-newergeneration-drugeluting-stents

U2 - 10.1016/j.jacc.2017.09.1029

DO - 10.1016/j.jacc.2017.09.1029

M3 - Article

VL - 70

SP - B333

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 18

ER -